HUNTSVILLE (October 30, 2025) – Scientists at Score Pharma, a therapeutics company located on the HudsonAlpha Institute for Biotechnology campus, believe they’ve found a way to make existing antibody
therapies for cancer significantly more potent.

The company claims that by making a small structural change during the upstream biologics process for
existing antibody therapeutics, the cancer cell killing mechanism of that specific therapeutic is greatly
improved. Through library screening, Score has identified tens of thousands of potential modulators for
its patented (Japan) and patent-pending (US, EU) process technology that will act as the duplicatable
platform for improvement of commercially available therapies.

Score is now preparing to conduct scientific confirmation studies at Southern Research, targeting its first
clinical application in HER2-positive breast cancer.

“We couldn’t be happier with the results we’re seeing in our early studies,” said Jennifer Riggs-Sauthier,
Ph.D., Chief Development Officer & Vice President of Chemistry at Score Pharma. “Cancer takes the lives
of about 27,000 people every day. That’s one cancer death every three seconds. This advancement
brings us one step closer to the clinic – and ultimately, to helping patients benefit from stronger, more
effective antibody therapies.”

About Score Pharma Inc.
Score Pharma Inc. is dedicated to developing new, more potent antibody therapeutics by transforming
existing clinically proven antibody therapeutics for an improved patient response. Through a science-driven
strategy and disciplined execution, the company aims to deliver transformative outcomes for
patients and sustainable returns for shareholders.

Media Contact
Kip Wolf, Chief Operating Officer & Vice President, Business Development
kwolf@scorepharma.com or +1 717-376-6672